Taira Deborah A, Seto Brendan K, Davis James W, Seto Todd B, Landsittel Doug, Sumida Wesley K
Daniel K. Inouye College of Pharmacy, University of Hawaii, 677 Ala Moana Blvd, Suite 1025, Honolulu, Hawaii 96813.
AC# 0857, Keefe Campus Center, Amherst College, Amherst, MA 01002-5000.
J Pharm Health Serv Res. 2017 Dec;8(4):247-253. doi: 10.1111/jphs.12193. Epub 2017 Aug 7.
To examine racial/ethnic and regional differences in medication adherence in patients with diabetes taking oral anti-diabetic, anti-hypertensive, and cholesterol lowering medications and to identify the pharmacies and prescribers who serve these communities.
Administrative claims data was analyzed for members enrolled in a large health plan in Hawaii (2008-2010) with diabetes mellitus who were taking three types of medications: 1) oral anti-diabetic medications; 2) anti-hypertensive medications; 3) cholesterol lowering medications (n=5136). The primary outcome was medication adherence based on medication possession ratios. Multivariable logistic regression models were estimated to examine the association between race/ethnicity and region to adherence to each drug class separately, followed by non-adherence to all three. Covariates included age, gender, education level, chronic conditions, copayment level, and number of prescribers and pharmacies from which the patients received their medications.
After adjustment for other factors, Filipinos [OR=0.58, 95%CI(0.45,0.74)], Native Hawaiians [OR=0.74, 95%CI(0.56,0.98)], and people of other race [OR=0.67, 95%CI(0.55,0.82)] were significantly less adherent to anti-diabetic and anti-hypertensive medications than Japanese. For cholesterol-lowering medications, all racial and ethnic groups were significantly less adherent than Japanese, except mixed race. We also found that different racial/ethnic groups tended to use different pharmacies and prescribers, particularly in rural areas.
Adherence differed by race/ethnicity as well as age and region. Qualitative research involving subgroups (e.g. Filipinos, Native Hawaiians, people under age 50) is needed to identify how to adapt and enhance the effects of interventions shown to be efficacious in prior studies.
研究服用口服抗糖尿病药、抗高血压药和降胆固醇药的糖尿病患者在药物依从性方面的种族/民族和地区差异,并确定为这些群体提供服务的药房和开处方者。
对夏威夷一个大型健康计划(2008 - 2010年)中患有糖尿病且正在服用三种药物的成员的行政索赔数据进行分析:1)口服抗糖尿病药物;2)抗高血压药物;3)降胆固醇药物(n = 5136)。主要结局是基于药物持有率的药物依从性。估计多变量逻辑回归模型,分别研究种族/民族和地区与每种药物类别依从性之间的关联,然后是对所有三种药物的不依从情况。协变量包括年龄、性别、教育水平、慢性病、自付费用水平以及患者接受药物治疗的开处方者和药房数量。
在对其他因素进行调整后,菲律宾人[比值比(OR)= 0.58,95%置信区间(CI)(0.45,0.74)]、夏威夷原住民[OR = 0.74,95%CI(0.56,0.98)]以及其他种族的人[OR = 0.67,95%CI(0.55,0.82)]在抗糖尿病和抗高血压药物的依从性方面显著低于日本人。对于降胆固醇药物,除了混血种族外,所有种族和民族群体的依从性均显著低于日本人。我们还发现,不同种族/民族群体倾向于使用不同的药房和开处方者,尤其是在农村地区。
依从性因种族/民族以及年龄和地区而异。需要开展涉及亚组(如菲律宾人、夏威夷原住民、50岁以下人群)的定性研究,以确定如何调整和增强先前研究中显示有效的干预措施的效果。